In a chilling audit that pierces the gilded façade of biotech ambition, auditors Katie and Marcus confront the grim reality behind Unity Biotechnology's $700 million IPO. As the South San Francisco fog rolls in, Marcus, with his cynical wit, grapples with the "metabolic bankruptcy" looming over the company, while Katie, precise and clinical, dissects the data on UBX1325 and its "senolytic" promise. They delve into the selective elimination of senescent cells, the "cellular dead wood" that Unity claims to clear, but Marcus questions the catch, hinting at a deeper "Senolytic Fallout" – the moment youth itself became a toxic asset.